News

Hydroxychloroquine Debate Rages in Federal Medicine


 

Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases, and one of the main spokespersons for science in the hydroxychloroquine debate, has continued to try to make his concerns clear: “I think we’ve got to be careful that we don’t make that majestic leap to assume this is a knockout drug,” he said in late March. “We still need to do the kinds of studies that definitively prove whether any intervention—not just this one, any intervention—is truly safe and effective.”

Pages

Recommended Reading

COVID-19 hits physician couple: Dramatically different responses
Federal Practitioner
Treating rectal cancer in the COVID-19 era: Expert guidance
Federal Practitioner
ASCO announces its own COVID-19 and cancer registry
Federal Practitioner
ABIM grants MOC extension
Federal Practitioner
ASH tackles COVID-19 with hematology-related FAQ, promotes new registries
Federal Practitioner
Troponins touted as ‘ally’ in COVID-19 triage, but message is nuanced
Federal Practitioner
Remdesivir tops list of promising COVID-19 treatments in review of nearly 300 trials
Federal Practitioner
What do early remdesivir data suggest?
Federal Practitioner
SARS-CoV-2 may confound seasons, persist in warmer months, report shows
Federal Practitioner
AMA asks HHS for ‘immediate’ aid to ease clinicians’ COVID-19 ‘financial peril’
Federal Practitioner

Related Articles